Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ELISA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    560 result(s) found for: ELISA. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-003068-29 Sponsor Protocol Number: P170934J Start Date*: 2018-11-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2)
    Medical condition: Asplenic patients at risk for invasive pneumococcal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10041642 Splenectomy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001419-64 Sponsor Protocol Number: NOR-107 Start Date*: 2014-01-24
    Sponsor Name:Takeda Vaccines (Montana), Inc.
    Full Title: A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuv...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002584-63 Sponsor Protocol Number: VAC31518COV2001 Start Date*: 2020-09-02
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults ...
    Medical condition: Healthy Volunteers (Prevention of COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Restarted) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000767-26 Sponsor Protocol Number: 700401 Start Date*: 2005-05-09
    Sponsor Name:Baxter AG
    Full Title: Open-label follow-up study to investigate the seropersistence of TBE antibodies and the booster response to a tick-borne encephalitis vaccine in children and adolescents aged 3 - 18 years.
    Medical condition: Tick-borne encephalitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011357-41 Sponsor Protocol Number: 112772 Start Date*: 2009-07-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the fir...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000768-19 Sponsor Protocol Number: 700501 Start Date*: 2005-08-02
    Sponsor Name:Baxter Vaccine AG
    Full Title: Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approximately 3 Years after a Booster Vaccination with FSME-IMMUN 0.25 ml Junior in Children
    Medical condition: Tick-borne encephalitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000369-44 Sponsor Protocol Number: 111375 Start Date*: 2009-03-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first v...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003941-24 Sponsor Protocol Number: Td528 Start Date*: 2016-01-13
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur’s Tdap Combined Vaccine (ADACEL) as a Booster Dose, versus Local DT Vaccine in Healthy Children or versus Local Td Vaccine in Healthy Adolescents and Adu...
    Medical condition: Active immunization against tetanus, diphtheria and pertussis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    18.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    18.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001584-20 Sponsor Protocol Number: 207543 Start Date*: 2017-10-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-se...
    Medical condition: Healthy volunteers (active immunization for the prevention of disease caused by influenza virus)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000255-50 Sponsor Protocol Number: 207347 Start Date*: 2018-03-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three ...
    Medical condition: Healthy volunteers (to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of vaccination in the primary study)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003379-37 Sponsor Protocol Number: VLA15-201 Start Date*: 2019-05-20
    Sponsor Name:Valneva Austria GmbH
    Full Title: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER...
    Medical condition: Prevention against Lyme borreliosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025169 Lyme disease PT
    20.0 10021881 - Infections and infestations 10025170 Lyme's disease LLT
    20.0 10021881 - Infections and infestations 10067559 Lyme borreliosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000778-20 Sponsor Protocol Number: NOR-202 Start Date*: 2014-07-04
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in...
    Medical condition: Prevention of gastroenteritis caused by norovirus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10068189 Gastroenteritis norovirus PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001325-14 Sponsor Protocol Number: 580299/008 Start Date*: 2004-08-12
    Sponsor Name:GlaxoSmithKline SA
    Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit...
    Medical condition: cervical cancer => study is conducted in healthy female
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005354-35 Sponsor Protocol Number: E2I43 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR INTERNATIONAL
    Full Title: Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™), Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dos...
    Medical condition: Healty volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellul...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005801-14 Sponsor Protocol Number: VAC31518COV3003 Start Date*: 2021-02-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults
    Medical condition: Healthy Volunteers (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003094-15 Sponsor Protocol Number: V98_06E1 Start Date*: 2016-02-11
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subj...
    Medical condition: Healthy person immune response to a second dose of Group B Streptococcus polysaccharide capsule antigens
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10053588 Group B streptococcus neonatal sepsis PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003610-15 Sponsor Protocol Number: RITUXVAS Start Date*: 2005-12-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.
    Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002872-41 Sponsor Protocol Number: ELR100710 Start Date*: 2005-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis
    Medical condition: Seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003310-14 Sponsor Protocol Number: SHO20190708 Start Date*: 2019-12-05
    Sponsor Name:Department of Dermatology, Bispebjerg Hospital
    Full Title: Laser immunotherapy with and without topical anti-PD1 in basal cell carcinomas
    Medical condition: Basal cell carcinoma in 24-30 patients
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005105-20 Sponsor Protocol Number: V48P4E3 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-de...
    Medical condition: Prophylaxis: Tick-borne-encephalitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 14:44:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA